Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

Xia Y, Yeddula N, Leblanc M, Ke E, Zhang Y, Oldfield E, Shaw RJ, Verma IM.

Nat Cell Biol. 2012 Feb 12;14(3):257-65. doi: 10.1038/ncb2428. Erratum in: Nat Cell Biol. 2015 Apr;17(4):532.

2.

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.

Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3.

PMID:
24011934
3.

Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer.

Thu KL, Pikor LA, Chari R, Wilson IM, Macaulay CE, English JC, Tsao MS, Gazdar AF, Lam S, Lam WL, Lockwood WW.

J Thorac Oncol. 2011 Sep;6(9):1521-9. doi: 10.1097/JTO.0b013e3182289479.

4.

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M.

Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.

5.

Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.

Yu JA, Mauchley D, Li H, Meng X, Nemenoff RA, Fullerton DA, Weyant MJ.

J Thorac Cardiovasc Surg. 2012 Nov;144(5):1185-91. doi: 10.1016/j.jtcvs.2012.08.003.

6.

RASSF1C modulates the expression of a stem cell renewal gene, PIWIL1.

Reeves ME, Baldwin ML, Aragon R, Baldwin S, Chen ST, Li X, Mohan S, Amaar YG.

BMC Res Notes. 2012 May 16;5:239. doi: 10.1186/1756-0500-5-239.

7.

Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).

Wang IC, Ustiyan V, Zhang Y, Cai Y, Kalin TV, Kalinichenko VV.

Oncogene. 2014 Nov 13;33(46):5391-6. doi: 10.1038/onc.2013.475. Epub 2013 Nov 11.

PMID:
24213573
8.

Selective requirement for Mediator MED23 in Ras-active lung cancer.

Yang X, Zhao M, Xia M, Liu Y, Yan J, Ji H, Wang G.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):E2813-22. doi: 10.1073/pnas.1204311109. Epub 2012 Sep 17.

9.

RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.

Eur J Cancer. 2011 Oct;47(15):2353-63. doi: 10.1016/j.ejca.2011.05.006. Epub 2011 Jun 15.

PMID:
21680174
10.

Aerosol delivery of lentivirus-mediated O-glycosylation mutant osteopontin suppresses lung tumorigenesis in K-ras (LA1) mice.

Minai-Tehrani A, Chang SH, Kwon JT, Hwang SK, Kim JE, Shin JY, Yu KN, Park SJ, Jiang HL, Kim JH, Hong SH, Kang B, Kim D, Chae CH, Lee KH, Beck GR Jr, Cho MH.

Cell Oncol (Dordr). 2013 Feb;36(1):15-26. doi: 10.1007/s13402-012-0107-3. Epub 2012 Oct 16.

PMID:
23070870
11.

Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.

Hill KS, Erdogan E, Khoor A, Walsh MP, Leitges M, Murray NR, Fields AP.

Oncogene. 2014 Apr 17;33(16):2134-44. doi: 10.1038/onc.2013.147. Epub 2013 Apr 22.

12.

ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells.

Botta GP, Reichert M, Reginato MJ, Heeg S, Rustgi AK, Lelkes PI.

Neoplasia. 2013 Apr;15(4):359-72.

13.

MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation.

Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16570-5. doi: 10.1073/pnas.1207917109. Epub 2012 Sep 24. Erratum in: Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10389.

14.

Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo.

Guo X, Wang W, Hu J, Feng K, Pan Y, Zhang L, Feng Y.

Anat Rec (Hoboken). 2012 Dec;295(12):2114-21. doi: 10.1002/ar.22571. Epub 2012 Sep 7.

15.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.

16.

The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.

Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T.

Blood. 2009 Sep 17;114(12):2448-58. doi: 10.1182/blood-2008-09-181008. Epub 2009 Jul 23.

17.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.

Breast Cancer Res. 2007;9(6):R76.

18.

Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.

Singel SM, Batten K, Cornelius C, Jia G, Fasciani G, Barron SL, Wright WE, Shay JW.

Breast Cancer Res. 2014 Mar 19;16(2):R28. doi: 10.1186/bcr3629.

19.

The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy.

Peinado C, Kang X, Hardamon C, Arora S, Mah S, Zhang H, Ngolab J, Bui JD.

Immunology. 2013 Jun;139(2):265-74. doi: 10.1111/imm.12080.

20.

Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines.

Reed MF, Zagorski WA, Howington JA, Zilfou JT, Knudsen ES.

Ann Thorac Surg. 2006 Jul;82(1):249-53.

PMID:
16798224
Items per page

Supplemental Content

Write to the Help Desk